drugset / Trial / NCT03100253
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
RandomizedParallel-groupSingle-blindTreatment
Summary
To compare the efficacy of switching to a different molecular target (from TNF to IL6) versus cycling to a second TNF inhibitor in patients with active RA, who have not adequately responded to a previous treatment with a first anti-TNF.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | — | — |
| Comparator | Certolizumab Pegol | Protein / enzyme biologic | — | — |
| Comparator | Etanercept | Protein / enzyme biologic | — | — |
| Comparator | Golimumab | Monoclonal antibody | — | — |
| Comparator | Infliximab | Monoclonal antibody | — | — |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Intravenous |